Lifestyle modifications like healthy eating and physical activity are foundational in obesity management. However, for some individuals, these lifestyle modifications are not enough to achieve long-term health benefits, and an anti-obesity medication is needed. Anti-obesity medications, or weight loss medications, specifically a class of glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as FDA-approved pharmaceutical tools for weight loss.

GLP-1 stands for glucagon-like peptide-1, which is a hormone produced in our gut. It is secreted by the intestinal cells in response to meals, and then travels in the blood and enters the brain. It exerts its main effects by releasing insulin, slowing gastric emptying, increasing feelings of fullness, and reducing appetite.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a type of medication originally developed to treat type 2 diabetes but are now being used for the treatment of obesity. In obesity care, GLP-1RAs work by reducing appetite and feelings of hunger, slowing the release of food from the stomach, and increasing the feelings of fullness after eating.

The weight loss results for GLP-1RAs can vary depending on the individual, their response to side effects, and other factors such as diet and exercise. However, clinical studies have shown that these medications can lead to significant weight loss in many people, ranging from 5-15% weight loss.

The most common side effects associated with GLP-1RAs are gastrointestinal symptoms (nausea, vomiting, and diarrhea) which are usually mild and occur in the first few weeks of treatment.

Similar to hypertension, long-term treatment with this medication is necessary to maintain weight loss outcomes, although the long-term effects of GLP-1RAs are not yet available.

GLP-1RAs approved for weight loss may be prescribed to adults with obesity (BMI ≥30) or to some adults who are overweight (BMI ≥ 27) who also have weight-related medical conditions such as type 2 diabetes, high cholesterol, or high blood pressure. We encourage you to talk with your primary care provider to discuss your eligibility and access to these medications.

No. Profile Plan does not prescribe medication nor provide treatment of medical conditions. All members are advised to discuss medication use with a primary care provider. Profile Plan believes it is vital that members maintain continual medical monitoring for the safety, efficacy, appropriateness, and tolerance of these medications as prescribed.

Profile Plan understands how critical it is to pair these medications with a comprehensive behavioral modification program along with a reduced-calorie diet and increased physical activity. By pairing GLP-1RA use in conjunction with the Profile program, people looking to lose weight can enhance outcomes, work toward achieving long-term weight management, and improve overall health.

Yes! Consuming a diet rich in protein, fiber, vitamins, and minerals complements and benefits those taking these medications while on a reduced-calorie diet. Profile Plan offers a custom-designed set of plans that uniquely meet the needs of those who are taking anti-obesity medications.